Most Viewed Articles
Articles | Fulltext downloads | PDF downloads | Total downloads |
---|---|---|---|
Short CommunicationDriver mutations in oncogenesisFull text![]() ![]() ![]() Year: 2021, Volume: 6, Issue: 2, May-August DOI: 10.25259/IJMIO_26_2020 |
27,860 | 3,007 | 30,867 |
Review ArticleMini review: Molecular pathology of personalized medicine in cancer susceptibility syndromesFull text![]() ![]() ![]() Year: 2023, Volume: 8, Issue: 3, September-December DOI: 10.25259/IJMIO_12_2023 |
22,981 | 1,981 | 24,962 |
Original ArticleOutcomes with atezolizumab and bevacizumab in hepatocellular carcinoma – Real-world data from IndiaFull text![]() ![]() ![]() Year: 2023, Volume: 8, Issue: 3, September-December DOI: 10.25259/IJMIO_15_2023 |
21,872 | 1,859 | 23,731 |
EditorialChallenging conventional wisdom in molecular oncology: New perspectivesFull text![]() ![]() ![]() Year: 2023, Volume: 8, Issue: 3, September-December DOI: 10.25259/IJMIO_20_2023 |
21,850 | 1,838 | 23,688 |
Review ArticleMolecular oncology and the role of artificial intelligence in advancing cancer treatmentFull text![]() ![]() ![]() Year: 2023, Volume: 8, Issue: 3, September-December DOI: 10.25259/IJMIO_17_2023 |
21,615 | 1,328 | 22,943 |
Short CommunicationOutcome of ivermectin and doxycycline in cancer patients with COVID-19: A positive experience in BangladeshFull text![]() ![]() ![]() Year: 2021, Volume: 6, Issue: 1, January-April DOI: 10.25259/IJMIO_30_2020 |
18,587 | 2,547 | 21,134 |
Case ReportLong-term efficacy of osimertinib in de novo exon 19 deletion with T790M in an epidermal growth factor receptor mutated lung cancer patient in IndiaFull text![]() ![]() ![]() Year: 2024, Volume: 9, Issue: 1, January-April DOI: 10.25259/IJMIO_16_2023 |
18,308 | 1,453 | 19,761 |
NewsEditorial board tribute to Dr. Amit VermaFull text![]() ![]() ![]() Year: 2021, Volume: 6, Issue: 3, September-December |
14,910 | 1,925 | 16,835 |
Review ArticleCan CDK 4/6 inhibitors be used in patients with visceral crises? Deviating from conventional teachingFull text![]() ![]() ![]() Year: 2022, Volume: 7, Issue: 2, May – August DOI: 10.25259/IJMIO_8_2022 |
12,500 | 4,230 | 16,730 |
Case ReportClinical experience of total body irradiation performed on Halcyon™ for a patient diagnosed with acute myeloid leukemiaFull text![]() ![]() ![]() Year: 2022, Volume: 7, Issue: 2, May – August DOI: 10.25259/IJMIO_5_2022 |
11,506 | 4,867 | 16,373 |
Case ReportSquamous cell carcinoma of lung presenting as “Sunray sign” in chest radiographFull text![]() ![]() ![]() Year: 2023, Volume: 8, Issue: 3, September-December DOI: 10.25259/IJMIO_6_2023 |
13,978 | 1,754 | 15,732 |
Case ReportHyperthermic intraperitoneal chemotherapy in primary peritoneal cancer: Our experience in a young maleFull text![]() ![]() ![]() Year: 2021, Volume: 6, Issue: 3, September-December DOI: 10.25259/IJMIO_16_2021 |
13,604 | 1,709 | 15,313 |
Cardio Oncology with ACOSIbrutinib and atrial fibrillation as cardiotoxicity – A new safety warning that impacts overall survivalFull text![]() ![]() ![]() Year: 2022, Volume: 7, Issue: 2, May – August DOI: 10.25259/IJMIO_1_2022 |
11,407 | 3,705 | 15,112 |
New Drug UpdateAmlodipine-induced inhibition of NFAT-2 nuclear translocation and its utility as an additive to immune checkpoint inhibitorFull text![]() ![]() ![]() Year: 2021, Volume: 6, Issue: 3, September-December DOI: 10.25259/IJMIO_13_2021 |
13,404 | 1,678 | 15,082 |
Review ArticlePotential therapeutic molecular targets for better outcomes for patients with lung cancerFull text![]() ![]() ![]() Year: 2023, Volume: 8, Issue: 2, May-August DOI: 10.25259/IJMIO_27_2022 |
14,397 | 669 | 15,066 |
Review ArticleSignaling pathways in pancreatic ductile adenocarcinoma and potential therapeutic targetsFull text![]() ![]() ![]() Year: 2023, Volume: 8, Issue: 3, September-December DOI: 10.25259/IJMIO_29_2022 |
13,513 | 1,537 | 15,050 |
Review ArticleCombination of PARPi and anti-PD-L1 therapies in ovarian cancerFull text![]() ![]() ![]() Year: 2023, Volume: 8, Issue: 2, May-August DOI: 10.25259/IJMIO_28_2022 |
14,166 | 868 | 15,034 |
Original ArticleIncorporation of immunohistochemistry in the assessment of survival and prognosis of endometrial cancers: Are we ready for the change?Full text![]() ![]() ![]() Year: 2022, Volume: 7, Issue: 2, May – August DOI: 10.25259/IJMIO_2_2022 |
10,887 | 3,741 | 14,628 |
Review ArticleImmune dynamics of SARS-CoV-2 virus evolutionFull text![]() ![]() ![]() Year: 2022, Volume: 7, Issue: 1, January-April DOI: 10.25259/IJMIO_26_2021 |
10,124 | 3,947 | 14,071 |
Case SeriesDual driver in non-small cell lung carcinoma – therapeutic dilemmaFull text![]() ![]() ![]() Year: 2022, Volume: 7, Issue: 1, January-April DOI: 10.25259/IJMIO_22_2021 |
11,785 | 2,045 | 13,830 |
Review ArticleIs continuous infusion of high-dose ifosfamide, a safe option? Drug reviewFull text![]() ![]() ![]() Year: 2020, Volume: 5, Issue: 2, May-August DOI: 10.25259/IJMIO_21_2019 |
10,873 | 2,850 | 13,723 |
Review ArticleAdvances in immunotherapy for metastatic esophageal cancerFull text![]() ![]() ![]() Year: 2022, Volume: 7, Issue: 3, September-December DOI: 10.25259/IJMIO_14_2022 |
9,948 | 3,740 | 13,688 |
Case ReportL1CAM expressing, ZFTA:: NCOA1 fusion-positive supratentorial ependymoma: A case reportFull text![]() ![]() ![]() Year: 2023, Volume: 8, Issue: 3, September-December DOI: 10.25259/IJMIO_11_2023 |
12,296 | 1,041 | 13,337 |
Review ArticleImmuno-oncological era of breast cancer: A progressive path to better treatmentFull text![]() ![]() ![]() Year: 2022, Volume: 7, Issue: 2, May – August DOI: 10.25259/IJMIO_3_2022 |
8,582 | 4,682 | 13,264 |
Review ArticleThe evolving role of precision medicine in the management of advanced sarcomas – A mini reviewFull text![]() ![]() ![]() Year: 2021, Volume: 6, Issue: 3, September-December DOI: 10.25259/IJMIO_6_2021 |
11,251 | 1,978 | 13,229 |
EditorialNanobytesFull text![]() ![]() ![]() Year: 2019, Volume: 4, Issue: 3, September-December DOI: 10.25259/IJMIO_7_2019 |
6,367 | 6,644 | 13,011 |
Case ReportRedefining the treatment of metastatic uveal melanoma with immunotherapy – A case reportFull text![]() ![]() ![]() Year: 2022, Volume: 7, Issue: 2, May – August DOI: 10.25259/IJMIO_11_2022 |
10,659 | 2,341 | 13,000 |
Review ArticlePost-chemotherapy maintenance treatment by nicotinamide riboside, a poly ADP ribose polymerase 1 inhibitor, in BRCA mutated advanced ovarian cancer – A perspectiveFull text![]() ![]() ![]() Year: 2021, Volume: 6, Issue: 3, September-December DOI: 10.25259/IJMIO_12_2021 |
10,702 | 2,176 | 12,878 |
Review ArticleImmuno-oncology of differentiated thyroid cancerFull text![]() ![]() ![]() Year: 2021, Volume: 6, Issue: 2, May-August DOI: 10.25259/IJMIO_36_2020 |
10,054 | 2,683 | 12,737 |
Conference Review6th Molecular Oncology Society Conference: Improving patient survival by molecularly targeted therapiesFull text![]() ![]() ![]() Year: 2021, Volume: 6, Issue: 3, September-December DOI: 10.25259/IJMIO_20_2021 |
10,917 | 1,562 | 12,479 |
Brief CommentaryERBB and FGFR2 pathway inhibition in biliary tract cancers – Dawn of a new beginningFull text![]() ![]() ![]() Year: 2021, Volume: 6, Issue: 3, September-December DOI: 10.25259/IJMIO_10_2021 |
10,286 | 2,168 | 12,454 |
Review ArticleA compendium of population wide DNA methylation profile for oral cancer in IndiaFull text![]() ![]() ![]() Year: 2021, Volume: 6, Issue: 2, May-August DOI: 10.25259/IJMIO_2_2021 |
9,365 | 3,022 | 12,387 |
ErratumErratum for manuscript “Muir Torre Syndrome – An Indian Case report” (IJMIO_5_2020)Full text![]() ![]() ![]() Year: 2021, Volume: 6, Issue: 2, October DOI: 10.25259/IJMIO_05_2020_ER |
11,212 | 1,147 | 12,359 |
Case ReportComplete metabolic response with letrozole and palbociclib in advanced breast cancerFull text![]() ![]() ![]() Year: 2019, Volume: 4, Issue: 3, September-December DOI: 10.25259/IJMIO_2_2019 |
7,859 | 4,498 | 12,357 |
Case ReportUnusual presentation of an Epstein barr virus-negative extranodal natural killer/T cell lymphoma: A diagnostic dilemmaFull text![]() ![]() ![]() Year: 2022, Volume: 7, Issue: 1, January-April DOI: 10.25259/IJMIO_18_2021 |
10,527 | 1,717 | 12,244 |
Brief CommentaryBreast cancer prognostic tools: A promising Indian optionFull text![]() ![]() ![]() Year: 2020, Volume: 5, Issue: 2, May-August DOI: 10.25259/IJMIO_15_2020 |
8,404 | 3,727 | 12,131 |
EditorialCrucial crossroads: Making the right choice for first-line therapy in advanced urothelial cancerFull text![]() ![]() ![]() Year: 2024, Volume: 9, Issue: 1, January-April DOI: 10.25259/IJMIO_2_2024 |
10,244 | 1,469 | 11,713 |
Brief CommentaryBioactive lipid: A novel diagnostic approach for retinoblastoma in clinical managementFull text![]() ![]() ![]() Year: 2021, Volume: 6, Issue: 3, September-December DOI: 10.25259/IJMIO_7_2021 |
9,478 | 2,151 | 11,629 |
Letter to EditorLetter to editorFull text![]() ![]() ![]() Year: 2022, Volume: 7, Issue: 2, May – August DOI: 10.25259/IJMIO_10_2022 |
7,941 | 3,687 | 11,628 |
Case ReportMetastatic endometrial carcinoma responsive to pembrolizumabFull text![]() ![]() ![]() Year: 2021, Volume: 6, Issue: 1, January-April DOI: 10.25259/IJMIO_18_2020 |
6,711 | 4,886 | 11,597 |
Review ArticleHigh-dose nicotinamide, a histone deacetylase inhibitor (Sirtuin-1), can prevent emergence of treatment resistance in chronic myeloid leukemia – A perspectiveFull text![]() ![]() ![]() Year: 2024, Volume: 9, Issue: 1, January-April DOI: 10.25259/IJMIO_1_2024 |
10,519 | 1,050 | 11,569 |
Review ArticleUnderstanding immunotherapy and CAR-T-cells: A narrative reviewFull text![]() ![]() ![]() Year: 2024, Volume: 9, Issue: 1, January-April DOI: 10.25259/IJMIO_22_2023 |
10,432 | 1,135 | 11,567 |
Review ArticleResistance to poly ADP-ribose polymerase inhibitors and its clinical implicationsFull text![]() ![]() ![]() Year: 2022, Volume: 7, Issue: 2, May – August DOI: 10.25259/IJMIO_12_2022 |
7,397 | 4,158 | 11,555 |
Review ArticleCell biological basis of tumor relapse and recurrence – A help from yeast quiescent biology and neuronal quiescent cell biologyFull text![]() ![]() ![]() Year: 2020, Volume: 5, Issue: 1, January-April DOI: 10.25259/IJMIO_18_2019 |
6,370 | 5,070 | 11,440 |
Review ArticleUse of five-day chronomodulated prescription of palbociclib as myelopreservation drug along with Topotecan in recurrent extensive stage small cell lung carcinoma – A perspective articleFull text![]() ![]() ![]() Year: 2024, Volume: 9, Issue: 1, January-April DOI: 10.25259/IJMIO_3_2024 |
10,299 | 1,024 | 11,323 |
Review ArticleThe Cancer Genomic Atlas – “TO CONQUER CANCER”Full text![]() ![]() ![]() Year: 2021, Volume: 6, Issue: 2, May-August DOI: 10.25259/IJMIO_28_2020 |
8,838 | 2,466 | 11,304 |
Review ArticleImpact of 2013 ASCO/CAP guidelines on various HER2 reporting categories in breast cancer by fluorescent in-situ hybridization and Immunohistochemistry: A meta-analysis with systematic reviewFull text![]() ![]() ![]() Year: 2020, Volume: 5, Issue: 1, January-April DOI: 10.25259/IJMIO_17_2019 |
5,818 | 5,387 | 11,205 |
Review ArticleMolecular genetics changes in gallbladder carcinomaFull text![]() ![]() ![]() Year: 2020, Volume: 5, Issue: 2, May-August DOI: 10.25259/IJMIO_19_2019 |
7,720 | 3,375 | 11,095 |
Original ArticleReal World Outcomes of Check Point Inhibitors Immunotherapy in Renal and Urothelial Cancers in a Teratiary Care Cancer Center in IndiaFull text![]() ![]() ![]() Year: 2019, Volume: 4, Issue: 3, September-December DOI: 10.25259/IJMIO_1_2019 |
5,313 | 5,748 | 11,061 |
Case ReportA rare case of Exon 19 deletion transforming to Exon 20 insertion in a case of adenocarcinoma of lungFull text![]() ![]() ![]() Year: 2022, Volume: 7, Issue: 3, September-December DOI: 10.25259/IJMIO_13_2022 |
8,695 | 2,062 | 10,757 |